637 related articles for article (PubMed ID: 27308423)
1. Trial Watch: Proteasomal inhibitors for anticancer therapy.
Obrist F; Manic G; Kroemer G; Vitale I; Galluzzi L
Mol Cell Oncol; 2015; 2(2):e974463. PubMed ID: 27308423
[TBL] [Abstract][Full Text] [Related]
2. Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
Hasinoff BB; Patel D
Cardiovasc Toxicol; 2018 Dec; 18(6):557-568. PubMed ID: 29951728
[TBL] [Abstract][Full Text] [Related]
3. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Dou QP; Zonder JA
Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibitors.
Teicher BA; Tomaszewski JE
Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
[TBL] [Abstract][Full Text] [Related]
5. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
[TBL] [Abstract][Full Text] [Related]
6. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
7. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
8. The role of the ubiquitin proteasome system in lymphoma.
Suh KS; Tanaka T; Sarojini S; Nightingale G; Gharbaran R; Pecora A; Goy A
Crit Rev Oncol Hematol; 2013 Sep; 87(3):306-22. PubMed ID: 23541070
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma.
Jayaweera SPE; Wanigasinghe Kanakanamge SP; Rajalingam D; Silva GN
Front Oncol; 2021; 11():740796. PubMed ID: 34858819
[TBL] [Abstract][Full Text] [Related]
10. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
Tundo GR; Sbardella D; Santoro AM; Coletta A; Oddone F; Grasso G; Milardi D; Lacal PM; Marini S; Purrello R; Graziani G; Coletta M
Pharmacol Ther; 2020 Sep; 213():107579. PubMed ID: 32442437
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Adverse Events Associated with Multiple Myeloma Patients Treated with Proteasome Inhibitors.
Fujiwara M; Uchida M; Endo M; Goto M; Shimizu T
Oncology; 2023; 101(5):343-348. PubMed ID: 36889294
[TBL] [Abstract][Full Text] [Related]
12. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
[TBL] [Abstract][Full Text] [Related]
13. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
Shahshahan MA; Beckley MN; Jazirehi AR
Am J Cancer Res; 2011; 1(7):913-24. PubMed ID: 22016836
[TBL] [Abstract][Full Text] [Related]
14. [The proteasome - structural aspects and inhibitors: a second life for a validated drug target].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):1-23. PubMed ID: 34397372
[TBL] [Abstract][Full Text] [Related]
15. Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome.
Hasinoff BB
Arch Biochem Biophys; 2018 Feb; 639():52-58. PubMed ID: 29305052
[TBL] [Abstract][Full Text] [Related]
16. Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease.
Sherman DJ; Li J
Molecules; 2020 Feb; 25(3):. PubMed ID: 32033280
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitors: structure and function.
Nunes AT; Annunziata CM
Semin Oncol; 2017 Dec; 44(6):377-380. PubMed ID: 29935898
[TBL] [Abstract][Full Text] [Related]
18. The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
Schmidt M; Altdörfer V; Schnitte S; Fuchs AR; Kropp KN; Maurer S; Müller MR; Salih HR; Rittig SM; Grünebach F; Dörfel D
Neoplasia; 2019 Jul; 21(7):653-664. PubMed ID: 31132676
[TBL] [Abstract][Full Text] [Related]
19. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
Johnson DE
Endocr Relat Cancer; 2015 Feb; 22(1):T1-17. PubMed ID: 24659480
[TBL] [Abstract][Full Text] [Related]
20. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
